drugset / Trial / NCT00635245

CP-751871 In Treating Women With Early-Stage Breast Cancer That Can Be Removed By Surgery

NCT00635245

Open-labelTreatment

Summary

RATIONALE: Monoclonal antibodies, such as CP-751871, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. PURPOSE: This phase I trial is studying the side effects and best way to give CP-751871 in treating patients with early-stage breast cancer that can be removed by surgery.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Figitumumab Monoclonal antibody Intravenous

Indications